PCSK9 and cardiovascular disorder: Monoclonal antibodies and/or antisense therapy directed against PCSK9 and ANGPTL3 are FDA approved in other indications than cancers (cardiovascular disease, familial hypercholesterolemia), while inhibitors of Lp(a) are currently investigated in clinical trials (ex: Phase 3 trial NCT04023552).